FDA Approves Updated Label for Kisunla, Featuring New Dosing to Significantly Reduce ARIA-E Risk in Alzheimer's

MiNK Therapeutics' Allogeneic iNKT Cell Therapy Achieves Complete Remission in Metastatic Testicular Cancer

Synfini Secures $8.9M in Funding to Accelerate AI-Driven Small Molecule Drug Discovery

AbbVie and IGI Partner on ISB 2001: A Novel Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Recursion Takes Full Control of REV102: Accelerating AI-Driven Oral Therapy for Hypophosphatasia

MAIA Biotechnology Doses First Patient in Expanded Phase 2 Trial for Ateganosine in NSCLC

Miraterra acquires Trace Genomics, an Ag-tech company to unlock measurement and insights across soil, plants, and food

Myrtelle Begins Commercial Production of Gene Therapy for Canavan Disease

EMA Grants Nurix Therapeutics' Bexobrutideg (NX-5948) Orphan Drug Designation for Waldenström Macroglobulinemia

Hope for Rare Brain Cancers: MB-101 (CAR T-cells) from Mustang Bio Gains Orphan Drug Status for Astrocytomas and Glioblastoma

FDA Approves KalVista's EKTERLY®: The First Oral On-Demand Treatment for Hereditary Angioedema

FDA Grants Breakthrough Therapy Status to Lexeo Therapeutics' LX2006 for Friedreich Ataxia

ZEGFROVY® Gains FDA Accelerated Approval for NSCLC with EGFR Exon 20 Insertion Mutations with Thermo Fisher's Oncomine™ Dx as companion diagnostic test

FDA Accelerates Approval of Regeneron's Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma

AbbVie to Acquire Capstan Therapeutics to Transform Patient Care in Immunology

Clinical Development of ARGX-119 for Congenital Myasthenic Syndromes Accelerated by argenx

Plus Therapeutics Gains FDA Agreement for REYOBIQ™ Trial in Leptomeningeal Metastases

XtalPi and Pfizer Deepen Partnership for AI-Powered Drug Discovery

FDA Approves Gamifant: A Groundbreaking Treatment for Macrophage Activation Syndrome in Still's Disease

FDA Approves Takeda's GAMMAGARD LIQUID ERC: A Unique, Low IgA Immunoglobulin Therapy for Easier Patient Use

Push to Advance Cardiac RNA Therapeutics as Lexeo, Perceptive Xontogeny, and venBio Partner Up

Novartis Completes Acquisition of Regulus Therapeutics, Bolstering Renal Disease Pipeline

Evotec Leverages Multi-Omics in NURTuRE-AKI Collaboration to Combat Acute Kidney Injury

GeneDx Study Shows Urgent Need for Rapid Genomic Testing in Pediatric Inpatients

FDA Grants Priority Review to Syndax's Revuforj for Leukemia Treatment

Enhanced Genomics and ALBORADA Institute Team Up for Alzheimer's Drug Discovery

Plus Therapeutics Gains FDA Clearance for REYOBIQ™ to Treat Childhood Brain Cancer

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Klotho Neurosciences Partners with Okinawa Longevity Experts to Analyze Klotho Gene in Longest-Lived Population

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

ORYZON Advances Vafidemstat for Borderline Personality Disorder with FDA Phase III Protocol Submission

Fabric Genomics and Galatea Bio partner to deliver comprehensive genetic testing for common diseases

Illumina Seals SomaLogic Acquisition, Fast-Tracking Proteomics and Multiomics Goals

Telix Pharmaceuticals' Illuccix® Approved in U.S. for Pre-Taxane RLT Patient Selection

Updated Interim Data from Passage Bio's upliFT-D Study Highlights One-Time Gene Therapy for Frontotemporal Dementia

Astrazeneca's Datroway Approved in US to Treat Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Redosable, Eye Drop Gene Therapy KB803 Enters Phase 3 with First Patient Dosed by Krystal Biotech for Dystrophic Epidermolysis Bullosa Eye Complications

Symbiotic.blue Unites Oxford & Cambridge Science with Biotech Leadership to Reimagine AI Drug Discovery

FDA Approves Cycle Pharmaceuticals' HARLIKU™ (nitisinone) Tablets, a Breakthrough for Ultra-Rare Genetic Metabolic Disorder Alkaptonuria (AKU)

Incyte's Monjuvi® (tafasitamab-cxix) Gains FDA Approval for Relapsed/Refractory Follicular Lymphoma

Gilead's Yeztugo® (Lenacapavir) Becomes First and Only FDA-Approved 6-Month HIV Prevention Option

Prenetics Sells ACT Genomics to Delta Electronics in Deal Valued Up to $71.78 Million

LYMPHIR™ Poised for 2025 Launch: Citius Oncology Readies Breakthrough CTCL Therapy

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Capricor Therapeutics Gains Orphan Drug Status for Becker Muscular Dystrophy, Advances Duchenne Program

Arima Genomics Names Tom Willis CEO, Secures $22M Series C Funding

Lisata Therapeutics and GATC Health Partner to Accelerate AI-Powered Drug Development

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Phathom Pharmaceuticals Secures Full 10-Year Exclusivity for VOQUEZNA

KalVista Highlights Sebetralstat's Efficacy for HAE on Prophylaxis

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sanofi and Regeneron Announce Positive EVEREST Trial Results for Severe CRSwNP with Coexisting Asthma

Intellia Announces One-Time Gene-Editing Treatment Lonvo-z Shows Durable Three-Year Efficacy in HAE Patients

Incyte and QIAGEN Partner to Develop Companion Diagnostics for CALR-Mutant MPNs

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment

Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD)

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases

U.S. FDA Approves UroGen’s ZUSDURI™ as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in CharcotMarie-Tooth disease Type 2S

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

George Medicines announces FDA approval of WIDAPLIK™, a new single pill combination treatment for hypertension in adults